Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document C2015/397/06

    Prior notification of a concentration (Case M.7872 — Novartis/GSK (Ofatumumab Autoimmune Indications)) (Text with EEA relevance)

    OJ C 397, 28.11.2015, p. 20–20 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    Date of document:
    28/11/2015; Date of publication
    Author:
    European Commission
    Form:
    Announcements

    28.11.2015   

    EN

    Official Journal of the European Union

    C 397/20

    Prior notification of a concentration

    (Case M.7872 — Novartis/GSK (Ofatumumab Autoimmune Indications))

    (Text with EEA relevance)

    (2015/C 397/06)

    1.

    On 18 November 2015, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Novartis AG (‘Novartis’, Switzerland) acquires from GlaxoSmithKline plc (‘GSK’, United Kingdom), within the meaning of Article 3(1)(b) of the Merger Regulation, sole control of the rights to the autoimmune indications with respect to the pharmaceutical Ofatumumab, by way of purchase of assets.

    2.

    The business activities of the undertakings concerned are:

    —

    Novartis is a Swiss healthcare company, active worldwide in three broad areas of healthcare: pharmaceuticals, eye care and generics,

    —

    GSK is a British pharmaceutical company active worldwide in the areas of pharmaceuticals, vaccines and consumer health products.

    3.

    On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

    4.

    The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

    Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7872 — Novartis/GSK (Ofatumumab Autoimmune Indications), to the following address:

    European Commission

    Directorate-General for Competition

    Merger Registry

    1049 Bruxelles/Brussel

    BELGIQUE/BELGIË

    (1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

    Top